Authors

Latest:

Dr. Talamonti on Advantages with Minimally Invasive Surgery for Pancreatic Cancer

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the advantages of minimally invasive surgery for patients with pancreatic cancer.

Mark Scholz, MD

Latest:

Dr. Scholz on Significance of ARAMIS Trial in CRPC

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the significance of the ARAMIS trial in the treatment of patients with metastatic castration-resistant prostate cancer.

Mark Schroeder, MD

Latest:

Dr. Schroeder on Tolerability of Treatment For Myeloma

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

Mark Shapiro, MD, PhD

Latest:

Dr. Shapiro Discusses Bosutinib in CML

Mark Shapiro, MD, PhD, discusses bosutinib as treatment for patients with CML.

Mark Sisco, MD

Latest:

Dr. Sisco Discusses Complications After Bilateral and Unilateral Mastectomies with Immediate Reconstruction

Mark Sisco, MD, Clinical Assistant Professor, Division of Plastic and Reconstructive Surgery, NorthShore Univeristy HealthSystem, discusses the results of a NSQIP analysis of 30-day complications after bilateral versus unilateral mastectomy with immediate reconstruction

Mark Socinski, MD, University of Pittsburgh

Mark Stein, MD

Latest:

Dr. Stein on AR-Resistance in Prostate Cancer

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.

Mark T. Fleming, MD

Latest:

Dr. Fleming on the Rationale of the SPOTLIGHT Trial in Prostate Cancer

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

Mark W. Bustoros, MD

Latest:

Dr. Bustoros on Next-Generation Sequencing in Multiple Myeloma

Mark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.

Mark W. Karwal, MD, University of Iowa Health Care

Mark W. Kieran, MD, PhD

Latest:

Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant Disease

Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.

Marko Velimirovic, MD

Latest:

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

Markus Albertsmeier, MD

Latest:

Dr. Albertsmeier on Radiotherapy Improving the Local Control of Sarcoma

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses radiotherapy improving the local control for patients with sarcoma.

Markus Renschler, MD

Latest:

Dr. Renschler Discusses Updated Results of the MPACT Study

Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer.

Marsha Fahey

Latest:

Urology Practices Form Collaborative Partnerships With Specialty Pharmacy Providers

Novel formulations of specialty drugs have shifted the treatment of patients taking oncologic and biologic agents from infusion centers to the doctor's office.

Marshall Posner, MD

Latest:

Examining the Landscape: PD-1 Inhibitors in R/M NPC

Panelists discuss the efficacy of multiple PD-1 inhibitors studied in nasopharyngeal cancer (NPC), noting similar overall outcomes despite differences in trial designs and adverse effect profiles, challenges in direct comparisons due to crossover and varying chemotherapy backbones, and how limited US approvals impact clinical choice—yet collectively these data affirm the integral role of PD-1 blockade as a cornerstone of treatment.

Marta E. Heilbrun, MD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Martee Hensley, MD

Latest:

Dr. Martee Hensley on Trabectedin as a Treatment for Uterine Leiomyosarcoma

Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.

Martee L. Hensley, MD

Latest:

Dr. Hensley on dMRR and MSI-H Testing in Endometrial Cancer

Martee L. Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses DNA mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) testing for patients with endometrial cancer.

Martee L. Hensley, MD, Memorial Sloan Kettering Cancer Center